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Abstract 29 
Achilles tendon pathology (ATP) is a degenerative condition which exhibits excessive 30 
tenocyte apoptosis. Tumour necrosis factor receptor 1 (TNFR1), caspase-3 (CASP3) and 31 
caspase-8 (CASP8) are important regulators of apoptosis. To date, the effect of variation 32 
within the genes for TNFR1 and CASP3 as risk factors for ATP have not been described. 33 
There is evidence that two single nucleotide polymorphisms (SNPs) within the CASP8 gene 34 
are associated with ATP, but only in populations from the Southern Hemisphere. The primary 35 
aim of this study was to determine whether SNPs within the TNFRSF1A and CASP3 genes 36 
were associated with ATP in British Caucasians. We additionally sought to determine 37 
whether copy number variation (CNV) within the CASP8 gene was associated with ATP. We 38 
recruited 262 (131 ATP cases and 131 asymptomatic controls) Caucasian participants for 39 
this genetic association study and used quantitative PCR with chi-squared (χ2) tests and 40 
ANOVA to detect significant associations. We found no association between the TNFRSF1A 41 
rs4149577 (p = 0.561), CASP3 rs1049253 (p = 0.643) and CASP8 copy number variants (p 42 
= 0.219) and ATP. Likewise, when we tested potential interactions between gender, 43 
genotype and the risk of ATP, we found no association with the variants investigated. In 44 
conclusion, the TNFRSF1A, CASP3 and CASP8 gene variants were not associated with ATP 45 
in British Caucasians. 46 
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1. Introduction 57 
The Achilles tendon is prone to damage and rupture1. Increased stress on tendons during 58 
exercise can cause such damage in both professional and recreational athletes, typically as 59 
a result of repetitive mechanical loading2,3,4. Achilles tendon pathology (ATP) can manifest as 60 
either insertional or noninsertional pathologies1,5. Alternatively the pathology can present as 61 
partial or complete rupture1,5 and lead to long-term incapacitation and a reduction in physical 62 
activity1. 63 
 64 
A range of factors, including genetics, have been shown to increase the risk of ATP4,6-8. For 65 
example, genes that encode proteins with a role in maintaining the integrity of the tendon 66 
extracellular matrix (ECM) have been shown to associate with ATP4,6,8. Apoptosis is a normal 67 
mechanism in tendon healing to remove damaged tenocytes9, however, relatively little is 68 
known about genetic variation within genes involved in apoptosis and the risk of ATP. 69 
Previous work in this area has been limited to variants within the CASP8 (rs384129, 70 
rs1045485), NOS2 (rs2779249) and NOS3 (rs1799983) genes in two cohorts from the 71 
Southern Hemisphere (South Africa and Australia)10. 72 
 73 
The TNFRSF1A gene encodes tumour necrosis factor receptor 1 (TNFR1), a cell receptor 74 
that can signal apoptosis in response to the pro-inflammatory cytokine tumour necrosis 75 
factor-alpha (TNF-α)11,12. TNFR1 mRNA and protein have recently been identified in human 76 
Achilles tendon12 and in cultured tenocytes13. Importantly TNFR1 is known to be highly 77 
expressed in tenocytes isolated from Achilles tendinosis12 but the functional or pathologic 78 
significance of this is not clear. Single nucleotide polymorphisms (SNPs) within the 79 
TNFRSF1A gene, especially the rs4149577 variant, have previously been associated with 80 
other musculoskeletal 14 and inflammatory diseases15. However, the role of this variant as a 81 
risk factor for ATP has not been investigated. 82 
 83 
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Caspases form a family of proteases that are important in the regulation of apoptosis16. 84 
Caspase-3 can selectively cleave target proteins after aspartate residues in their primary 85 
sequence16,17. Although apoptosis can be activated through a number of complex pathways, 86 
caspase-3 appears to have a critical role in chromatin condensation and DNA 87 
fragmentation18. The CASP3 rs1049253 variant resides within the 3’ untranslated region 88 
(UTR) of the gene and can influence the binding of miR-885-5p to CASP3 mRNA19. Guan et 89 
al. (2013) showed that the CC genotype of this variant influences levels of CASP3 mRNA 90 
expression19. Like the TNFRSF1A gene, the role of the CASP3 rs1049253 variant in 91 
predisposing to ATP is unknown. 92 
 93 
Another important regulator of apoptosis is caspase-8. Caspase-8, encoded by the CASP8 94 
gene, can activate downstream effector caspases11. It is know to regulate apoptosis of 95 
tendon fibroblasts9. Regulating the balance between synthesis and degradation is essential 96 
in maintaining ECM homeostasis and the removal of damaged tendon fibroblasts during 97 
normal tendon turnover is important9. However, atypical tenocyte apoptosis has been shown 98 
in tendinopathy, with elevated expression levels of CASP8 observed10. Two SNPs within the 99 
CASP8 gene have been associated with ATP10 but the role of larger scale variation within 100 
this gene as a risk factor has not been considered. 101 
 102 
Although our understanding of the role that SNPs play in ATP is growing4,6,8,10, there has yet 103 
to be an investigation into the influence of copy number variation (CNV) as a predisposing 104 
factor. Copy number variants (CNVs) are segments of DNA greater than 1kb in size, which 105 
show altered copy number (CN) when compared to a reference genome20. CNVs can 106 
influence phenotypes by altering gene dosage and disrupting coding sequences of DNA21. 107 
Indeed, predisposition to certain diseases appears to be associated with CNV21,22. The 108 
CASP8 gene is known to harbour a CN variant that spans intron 11 - intron 12 of the 109 
nucleotide sequence (as reported in the Database of Genomic Variants (DGV) 110 
(http://projects.tcag.ca/variation/)). With regard to the role of caspase 8 in apoptosis, and as 111 
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SNPs within this gene have been associated with ATP10, we considered that CNV within 112 
CASP8 might predispose to ATP. Additionally, for the reasons outlined in the preceding 113 
paragraphs, we decided to investigate whether the TNFRSF1A rs4149577 and CASP3 114 
rs1049253 variants were additional risk factors for this pathology. 115 
 116 
2. Methods 117 
One hundred and thirty one British Caucasian participants diagnosed with ATP and 131 118 
asymptomatic British Caucasian controls (CON) were recruited for this genetic association 119 
study. ATP participants were recruited through The County Clinic in Northampton, UK. 120 
Participants within the CON group (physically active individuals without any history of ATP) 121 
were recruited from the East Midlands region of the UK. Cases of Achilles tendinopathy 122 
typically presented with gradual progressive pain with early-morning pain/stiffness in the 123 
Achilles tendon area. Affected individuals were diagnosed by the clinical author using the 124 
criteria published elsewhere5,23,29 Diagnosis of tendinopathy was objectively confirmed, in 125 
most cases, by MRI of the affected Achilles tendon. The ATP group consisted of participants 126 
with noninsertional (N=47) or insertional (N=29) tendinopathy along with those presenting 127 
with partial or complete Achilles tendon rupture (N=23). We further recruited an additional 29 128 
cases with more than one type of tendinopathy (insertional and noninsertional). Three 129 
individuals originally recruited as controls later self-reported symptoms of ATP but the 130 
specific type of tendinopathy for these was not obtained. Subsequent to initial diagnosis, 15 131 
cases with Achilles tendinopathy went on to develop ruptures. As each subpathology 132 
(insertional, non-insertional and rupture) was relatively small in number we pooled all cases 133 
as having the combined condition of Achilles tendon pathology and this was the main 134 
phenotype we chose to investigate. Additional association analysis on each subpathology 135 
was, nevertheless, investigated but this was statistically underpowered due to the small 136 
sample sizes. All participants completed a physical activity/medical history/injury 137 
questionnaire. and gave written, informed consent. The study was approved by the Research 138 
Ethics Committee of the University of Northampton, United Kingdom. 139 
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 140 
DNA was extracted from 2 mL of saliva collected using ORAGENE-DNA kits (OG-500) and 141 
DNA purification was carried out using the prepIT-L2P DNA extraction kit (DNA Genotek Inc., 142 
Ontario, Canada). Quantitative PCR (qPCR) reactions were run on a StepOnePlus Real-143 
Time PCR System (Applied Biosystems, Foster City, California, USA) in 96-well plates, using 144 
fluorescence-based TaqMan assays. The genotyping assays for the TNFRSF1A rs4149577, 145 
CASP3 rs1049253 and CASP8 variants were selected from Applied Biosystems. PCR 146 
reactions contained probes and primers in a mastermix containing AmpliTaq DNA 147 
Polymerase Gold and 10 ng of DNA. The cycling conditions consisted of a holding phase at 148 
95 °C for 10 min, followed by 40 cycles of denaturing at 95 °C for 15 s and 149 
annealing/extension at 60 °C for 1 min. Quality control for our SNP genotyping consisted of 150 
running both within and between plate replicates to assess for reproducibility in genotype call 151 
along with the running of 4 no DNA template controls (NTC) in each qPCR run. For the copy 152 
number assays, each sample was repeated in quadruplicate along with the inclusion of 153 
NTCs.  154 
 155 
For the TNFRSF1A rs4149577 and CASP3 rs1049253 SNPs, the TaqMan Genotyping 156 
Assays (C_2645708_10 and C_11683739_10 respectively) contained both FAM and VIC 157 
reporter dye labelled probes to discriminate between genotypes, along with ROX dye as the 158 
passive reference. Genotypes were called using StepOne Software version 2.1 (Applied 159 
Biosystems, Foster City, California, USA). CNV spanning intron 11 - intron 12 of the CASP8 160 
gene was determined using the TaqMan Copy Number Assay Hs02601709_cn along with 161 
the reference assay for RNase P. QPCR was performed as a duplex reaction and all CN 162 
data were exported into CopyCaller Software version 2.0 (Applied Biosystems, Foster City, 163 
California, USA) for calculation of discrete and continuous CN. CN of the target gene was 164 
normalised relative to the reference RNase P gene. We used CopyCaller Software to 165 
calculate confidence and z-score quality metrics. CN calls were inspected for reproducibility 166 
and accepted with a z-score <1.75. To establish PCR efficiency of both assays (CASP8 and 167 
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RNase P), qPCR was carried out using serial dilutions of genomic DNA. Efficiency (E) was 168 
calculated using the equation E=10(-1/m)-1 24. 169 
 170 
Data were analysed using IBM SPSS Statistics version 20 (IBM Corp. Armonk, NY). One-171 
way analysis of variance (ANOVA) was used to determine any significant differences 172 
between the characteristics (age, height, weight, BMI) of the ATP and CON groups. A 173 
Pearson’s chi-squared (χ2) test was used to determine any significant differences between 174 
the gender of the ATP and CON groups. A χ2 or Fisher’s exact test was used to analyse for 175 
differences in genotype and allele frequency distributions for the TNFRSF1A rs4149577 and 176 
CASP3 rs1049253 variants, as well as differences in discrete CN (<2, =2, >2 copies) for the 177 
CASP8 gene in the ATP and CON groups. Differences in continuous CN values between 178 
ATP and CON groups were analysed using a non-parametric Mann Whitney U-test. Data 179 
were also analysed by gender and, where appropriate, comparisons were also made 180 
between the ATP subpathologies and CON groups. In all analyses, significance was 181 
accepted at p < 0.05. Hardy-Weinberg equilibrium (HWE) was established using a HWE 182 
calculator (Michael H. Court, 2005-2008) accessed from 183 
www.tufts.edu/~mcourt01/Documents/Court lab - HW calculator.xls. P < 0.05 was considered 184 
to be a deviation from HWE. The statistical power of our SNP analysis was calculated using 185 
Quanto version 1.2 (http://hydra.usc.edu/gxe)25. Assuming an odds ratio (OR) of 2.2 and a 186 
recessive mode of inheritance, our analysis had 80% power to detect associations at the p < 187 
0.05 significance level. For our CNV analysis we used sampsize (Version 0.6), available at 188 
http://sampsize.sourceforge.net/26 for a power calculation. With an assumed CN exposure 189 
frequency of 20%, without a specified mode of inheritance, our cohort size was sufficient for 190 
80% power. 191 
 192 
3. Results 193 
The CON and ATP groups were similarly matched for gender, height, weight and BMI. 194 
However, there was a significant difference in age (p = 0.019) between the CON (41.3 ± 195 
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11.3, n = 122) and ATP (45.1 ± 14.2, n = 127) groups. There was a small but significant 196 
difference in age between the CON and RUP groups (p=0.036). Full details of the study 197 
participant characteristics (including the TEN and RUP subgroups) can be seen in Table 1. 198 
The FAM labelled TaqMan Copy Number Assay and the VIC labelled Reference Assay 199 
RNase P gave PCR efficiencies of 106% and 104% respectively. We found no interaction 200 
between the variants investigated and participant characteristics for the entire cohort (data 201 
not shown). We also found that none of the variants investigated associated with either the 202 
insertional, noinsertional, rupture or mixed pathologies (P>0.05). However, investigating 203 
potential associations between the various subpathologies and genotype was not the focus 204 
of our study as the N values for each subpathology was small and analysis was statistically 205 
underpowered.   206 
 207 
Genotype and minor allele frequency (MAF) distributions for the TNFRSF1A rs4149577 and 208 
CASP3 rs1049253 variants, along with HWE p-values, are shown in Table 2. For the 209 
TNFRSF1A rs4149577 variant, the genotype (p = 0.561) and allele (p = 0.335) frequency 210 
distributions were not significantly different between the ATP and CON groups. There were 211 
no significant differences in genotype or allele frequencies between the male ATP and CON 212 
group (p = 0.561 and p = 0.371 respectively), nor between the female ATP and CON group 213 
(p = 0.916 and p = 0.680 respectively). 214 
 215 
For the CASP3 rs1049253 variant, there were no significant differences in genotype (p = 216 
0.643) or allele (p = 0.635) frequencies between the ATP and CON groups. There was no 217 
significant difference in genotype (p = 0.142) or allele (p = 0.104) frequencies between the 218 
female ATP and CON group. There was also no significant difference in genotype (p = 219 
0.072) or allele (p = 0.058) frequencies between the male ATP and CON group, although 220 
there was a trend towards significance. 221 
 222 
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CN frequency distributions (<2, =2, >2 copies) of the ATP and CON groups for the variant 223 
spanning intron 11 - intron 12 of the CASP8 gene are shown in Table 3. At this locus, 4 ATP 224 
and 2 CON participants were shown to have < 2 copies, while 10 ATP and 14 CON had > 2 225 
copies. When we compared the distribution of discrete CN between ATP and CON groups, 226 
we found no evidence of a significant difference (p = 0.219). Furthermore, there was no 227 
significant difference in CN between the male ATP and the CON group (p = 0.703) nor 228 
between the female ATP and CON group (p = 0.277). We also found that when we analysed 229 
CN data as a continuous variable with a Mann Whitney U-test, there were no significant 230 
differences between ATP and CON groups. This was also the case in gender specific 231 
analyses (data not shown). 232 
 233 
4. Discussion 234 
The TNFRSF1A rs4149577 variant does not appear to be associated with ATP in a British 235 
cohort. TNFR1 has a role in apoptosis and it is expressed at significantly higher levels in 236 
tenocytes from Achilles tendinosis compared to controls12. However, as we only investigated 237 
a single SNP within this gene (TNFRSF1A rs4149577), it is possible that other variants within 238 
the DNA sequence may modify the risk of ATP. For example, the TNFRSF1A rs4149577 239 
variant is an intronic SNP that is in linkage disequilibrium (LD) with a number of other 240 
variants, including TNFRSF1A rs1800693 and rs4149578 (www.ensembl.org), which have 241 
been associated with musculoskeletal and inflammatory diseases14,15,27. 242 
 243 
Nell et al. (2012) have previously reported that variants within the CASP8 gene were 244 
associated with Achilles tendinopathy in a South African and Australian cohort. Specifically, 245 
they showed that the CASP8 rs1045485 and rs3834129 SNPs were both associated with 246 
Achilles tendinopathy10. The copy number variant spanning intron 11 - intron 12 of the 247 
CASP8 gene that we investigated here overlaps the rs1045485 SNP investigated by Nell et 248 
al. (2012), but it is approximately 50 000 base pairs from the rs3834129 SNP. We found no 249 
association between CNV at this locus and ATP, in contrast to Nell et al. (2012). This might 250 
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be related to a number of factors. Firstly, SNPs like the CASP8 rs1045485 variant may have 251 
a more profound impact on the development of ATP, compared to larger-scale variants such 252 
as CNV. This assertion is supported by the fact that the CASP8 rs1045485 SNP is a non-253 
synonymous G>C polymorphism that results in an amino acid change (Asp302His), which 254 
may affect interaction with other proteins9. In contrast, the functional effect of altered CN at 255 
the CASP8 locus we investigated is presently unknown. Secondly, the association of this 256 
region of the CASP8 gene with ATP might be a population specific effect, as association with 257 
the CASP8 rs1045485 SNP was reported in South African and Australian cohorts10 and our 258 
data were obtained from British Caucasians. With this in mind, we would envisage further 259 
studies on this British cohort using the SNPs investigated by Nell et al (2012) to establish 260 
whether they specifically associate with ATP. This would confirm or refute any population 261 
difference with high resolution.  An additional haplotype based association study using these 262 
SNPs would also be worthwhile. 263 
 264 
Although we did not find an association between the CASP3 rs1049253 variant and the ATP 265 
group as a whole, we did observe that both genotype and allele frequency distributions 266 
approached significance when male CON and male ATP were compared. Furthermore, we 267 
did find a quantitative overrepresentation of the CC genotype in males with insertional 268 
tendinopathy compared to male controls (data not shown). However, a detailed statistical 269 
analysis of this was not possible due to the small number of males in our cohort who 270 
presented with this sub- pathology, nevertheless, it does warrant further investigation. 271 
 272 
Our study seems to exclude the TNFRSF1A rs4149577, CASP3 rs1049253 and CASP8 CN 273 
loci from a role in ATP. However, we must be cautious in interpreting these findings as the 274 
study has some limitations. Firstly, although our investigation was sufficiently powered to 275 
detect relatively large effect sizes given the total sample size of 262, it lacked power to detect 276 
associations with more modest effects. Secondly, while we found no association between 277 
discrete CN calls and ATP for the CASP8 locus, we were aware that it has been suggested 278 
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that rounding CN data into discrete calls might introduce a degree of error28. However, to 279 
circumvent this possible issue, we also analysed our CN data as a continuous variable and 280 
found a concordant lack of association that agreed with the discrete CN findings (data not 281 
shown). 282 
 283 
To our knowledge, no previous study has investigated whether the TNFRSF1A rs4149577 284 
and CASP3 rs1049253 variants were associated with ATP. Additionally, this was the first 285 
study to investigate whether genomic CNV (in this case within the CASP8 locus) was a 286 
possible predisposing factor for ATP. To date, studies on the genetics of ATP have been 287 
conducted predominantly in South African and Australian cohorts10,29-31 Our study was the 288 
first to investigate the effect of these variants in British-based individuals. 289 
 290 
In conclusion, the TNFRSF1A rs4149577, CASP3 rs1049253 and CASP8 variants do not 291 
associate with ATP. Although we recommend that this study be repeated in a larger cohort, 292 
and where possible using cases where only each subpathology is evident, these preliminary 293 
findings exclude three plausible candidate gene variants from a role in a common 294 
musculoskeletal pathology.  295 
 296 
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Table 1. General characteristics of the Achilles tendon pathology (ATP), tendinopathy (TEN), rupture (RUP) and control (CON) groups. 414 
  CON 
(n=131) 
ATP 
(n=131) 
p-value 
TEN 
(n=93) 
p-value 
RUPb 
(n=38) 
p-value 
  
Age (years)a 41.3 ± 11.3 (122) 45.1 ± 14.2 (127) 0.019 44.9 ± 13.8 (90) 0.036 45.6 ± 15.4 (37) 0.066 
Gender    (% male) 62.6 (82) 61.8 (81) 0.899 60.2 (56) 0.718 65.8 (25) 0.719 
Height (cm) 175.0 ± 10.5 (121) 172.6 ± 9.6 (128) 0.065 172.4 ± 9.1 (90) 0.058 173.3 ± 10.7 (38) 0.384 
Weight (kg) 80.5 ± 19.6 (122) 78.5 ± 15.2 (94) 0.416 77.5 ± 15.2 (64) 0.300 80.4 ± 15.1 (30) 0.996 
BMI (kg m-2) 25.7 ± 5.1 (122) 26.3 ± 4.1 (94) 0.401 26.0 ± 4.3 (64) 0.688 26.8 ± 3.7 (30) 0.285 
Values are expressed as means ± SD for study participant characteristics. The total number of participants (n) is in parentheses. cm: 415 
centimetres; kg: kilograms; m: metres.  416 
a
 Age of CON is age of recruitment, while age of ATP, TEN and RUP is age of initial injury. 417 
One-way ANOVA was used to analyse differences in the characteristics of CON vs. ATP, CON vs. TEN and CON vs. RUP groups. Significance 418 
was accepted when p < 0.05. 419 
bThe RUP group includes those that initially presented with rupture (N=23) and those that later developed ruptures from an initial diagnosis of 420 
tendinopathy (N=15). 421 
 422 
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Table 2. Genotype and allele frequency distributions of the TNFRSF1A rs4149577 and 423 
CASP3 rs1049253 variants within cases (ATP) and controls (CON). 424 
 CON ATP 
Male 
CON 
Male  
ATP 
Female 
CON 
Female 
ATP  
TNFRSF1A 
rs4149577 
  
  
  
N 131 131 82 81 49 50 
CC 23.7 (31) 21.4 (28) 25.6 (21) 23.5 (19) 20.4 (10) 18.0 (9) 
CT 48.9 (64) 45.0 (59) 47.6 (39) 42.0 (34) 51.0 (25) 50.0 (25) 
TT 27.5 (36) 33.6 (44) 26.8 (22) 34.6 (28) 28.6 (14) 32.0 (16) 
p-value  0.561  0.561  0.916 
MAF 48.1 (126) 43.9 (115) 49.4 (81) 44.4 (72) 45.9 (45) 43.0 (43) 
p-value  0.335  0.371  0.680 
HWE 0.806 0.327 0.660 0.177 0.849 0.888 
CASP3 
rs1049253 
  
  
  
N 131 130 82 80 49 50 
TT 62.6 (82) 61.5 (80) 68.3 (56) 58.8 (47) 53.1 (26) 66.0 (33) 
CT 34.4 (45) 33.1 (43) 30.5 (25) 32.5 (26) 40.8 (20) 34.0 (17) 
CC 3.1 (4) 5.4 (7) 1.2 (1) 8.8 (7) 6.1 (3) 0.0 (0) 
p-value  0.643  0.072  0.142 
MAF 20.2 (53) 21.9 (57) 16.5 (27) 25.0 (40) 26.5 (26) 17.0 (17) 
p-value  0.635  0.058  0.104 
HWE 0.461 0.700 0.326 0.233 0.742 0.148 
Values are expressed as a frequency (%) with number of participants (n) in parenthesis. 425 
HWE: Hardy-Weinberg equilibrium. MAF: minor allele frequency. Differences in genotype 426 
and allele frequencies between CON and ATP were analysed using a Pearson’s χ2 or 427 
Fisher’s exact test. Significance was accepted when p < 0.05. 428 
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 429 
Table 3. CN frequency distribution within the CASP8 gene in cases (ATP) and controls 430 
(CON). 431 
Group < 2 CN = 2 CN > 2 CN n p-value 
CON 2 46 14 62 - 
ATP 4 70 10 84 0.219 
      
Male CON 1 30 8 39 - 
Male ATP 1 44 7 52 0.703 
      
Female CON 1 16 6 23 - 
Female ATP 3 26 3 32 0.277 
Differences in discrete CN between CON and ATP were analysed as described in the 432 
Methods section. Significance was accepted when p < 0.05. 433 
 434 
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